FY2017 EPS Estimates for Ocular Therapeutix, Inc. Lifted by Cantor Fitzgerald (OCUL)

Marco Green
July 17, 2017

COPYRIGHT VIOLATION NOTICE: "Ocular Therapeutix (NASDAQ:OCUL) Receiving Somewhat Critical Press Coverage, Report Shows" was posted by BNB Daily and is the sole property of of BNB Daily. (OCUL) now has a value of $6.33 while the company's 52 week low is at $4.04, the shares dropped to the 52 week low on 08/03/16. Nationwide Fund Advisors' holdings in Ocular Therapeutix were worth $103,000 at the end of the most recent quarter.

Institutional investors have recently added to or reduced their stakes in the company. Columbus Circle Investors boosted its stake in Ocular Therapeutix by 131.4% in the first quarter. It is generally used to describe the high and low price of a stock or option during a given trading day or session. Ellington Management Group LLC now owns 21,200 shares of the biopharmaceutical company's stock valued at $177,000 after buying an additional 4,300 shares during the period. The company was maintained on Friday, July 14 by Morgan Stanley. JPMorgan Chase & Co. bought a new position in shares of Ocular Therapeutix during the first quarter valued at $3,394,000. Vanguard Group Inc. boosted its stake in Ocular Therapeutix by 24.0% in the first quarter.

Many analysts are providing their Estimated Earnings analysis for Ocular Therapeutix, Inc. and for the current quarter 4 analysts have projected that the stock could give an Average Earnings estimate of $-0.58/share. (OCUL) opened at 6.33 on Friday. Over the last three months, the shares of the company have changed -21.34% and performed -14.02% over the last six months. The company's market cap is $213.36 million. Latest closing price was 6.13% above its 50-day moving average and 23.92% above its 200-day moving average.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.10. The firm had revenue of $0.48 million during the quarter, compared to the consensus estimate of $0.51 million.

For a total return analysis, there is the -64.10% return on equity and the -80.20% return on assets to consider.

The Klein Law Firm announces the commencement of an investigation of Ocular Therapeutix, Inc. The correct version of this article can be viewed at https://www.com-unik.info/2017/07/17/fy2017-eps-estimates-for-ocular-therapeutix-inc-lifted-by-cantor-fitzgerald-nasdaqocul.html. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and worldwide copyright and trademark laws. The firm has "Outperform" rating given on Thursday, August 11 by JMP Securities.

The financial company has just set a price target of $8 on Ocular Therapeutix (NASDAQ:OCUL) shares. BTIG Research reissued a "buy" rating and issued a $13.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 21st. Morgan Stanley lowered shares of Ocular Therapeutix from an "overweight" rating to an "equal weight" rating and set a $16.00 price objective for the company.in a research note on Friday, June 23rd.

Among 6 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 4 have Buy rating, 0 Sell and 2 Hold. A 5 analysts rate it as either a buy or a strong buy, while 1 believe that investors should either steer clear of (NYSE:PEG) or, if they already own its stock, sell it.

For the Current Quarter, the growth estimate for Ocular Therapeutix, Inc.is -26.1%, while for the Next Quarter the stock growth estimate is -43.6%.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER